Dr Audrey Kong presents at ADA 2025
We would like to congratulate Dr Audrey Kong for her well received presentation at the American Diabetes Association’s annual conference of 2025. Dr Kong presented some of the preliminary results of our PARTNER study, which investigated use of a drug called Dapagliflozin.
The use of Dapagliflozin in individuals with type 1 diabetes may improve glucose levels, protect the kidneys and heart, and offer the potential for weight loss. However, taking Dapagliflozin can be associated with diabetic ketoacidosis (DKA). DKA is a life threatening condition that occurs when ketones build up in the body as a result of burning fat to make energy instead of glucose, which happens when there is insufficient amounts of insulin in the bloodstream. The aim of the PARTNER study was to monitor glucose and ketone levels concurrently using continuous glucose and ketone sensors while participants were taking Dapagliflozin , combined with an education program to reduce the risk of DKA.
Dr Kong presented the results of the first two weeks of the study, where the participants had not yet begun to take the study drug but were wearing the continuous ketone monitor. This allowed the research team to characterise the natural fluctuations of ketones in a large and diverse population of individuals with type 1 diabetes while they went about their daily lives.
This data provides important insights into the dynamic nature of free-living ketone levels in individuals with type 1 diabetes, which can help inform our growing understanding of the complex impact of type 1 diabetes on the entire body, not just on blood glucose levels.
Dr Audrey Kong presents at ADA 2025
We would like to congratulate Dr Audrey Kong for her well received presentation at the American Diabetes Association’s annual conference of 2025. Dr Kong presented some of the preliminary results of our PARTNER study, which investigated use of a drug called Dapagliflozin.
The use of Dapagliflozin in individuals with type 1 diabetes may improve glucose levels, protect the kidneys and heart, and offer the potential for weight loss. However, taking Dapagliflozin can be associated with diabetic ketoacidosis (DKA). DKA is a life threatening condition that occurs when ketones build up in the body as a result of burning fat to make energy instead of glucose, which happens when there is insufficient amounts of insulin in the bloodstream. The aim of the PARTNER study was to monitor glucose and ketone levels concurrently using continuous glucose and ketone sensors while participants were taking Dapagliflozin , combined with an education program to reduce the risk of DKA.
Dr Kong presented the results of the first two weeks of the study, where the participants had not yet begun to take the study drug but were wearing the continuous ketone monitor. This allowed the research team to characterise the natural fluctuations of ketones in a large and diverse population of individuals with type 1 diabetes while they went about their daily lives.
This data provides important insights into the dynamic nature of free-living ketone levels in individuals with type 1 diabetes, which can help inform our growing understanding of the complex impact of type 1 diabetes on the entire body, not just on blood glucose levels.